BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2017 -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that Bill Lis, chief executive officer, will present at the 2017 Morgan Stanley Global Healthcare Conference on Wednesday, September 13, at 1:00 p.m. Eastern Time in New York City.
The presentation will be webcast live and available for replay on Portola's website at www.portola.com in the Investor Relations section.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s first medicine Bevyxxa® (betrixaban), an oral, once-daily Factor Xa inhibitor, was approved by the U.S. Food and Drug Administration in June 2017. The company is also working to advance two clinical programs for andexanet alfa, a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a SYK/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective SYK inhibitors for inflammatory conditions. For more information, visit http://www.portola.com and follow the Company on Twitter @Portola_Pharma.
Investor Contact: Michele Mantynen Portola Pharmaceuticals [email protected] Media Contact: Julie Normart Pure Communications [email protected]
